Clinical

New findings from 2 abstracts presented at SABCS reveal T-DXd regimens enhance outcomes and tolerability for patients with high-risk HER2-positive early breast cancer.

More than one-quarter of US adults have a risk factor for severe RSV infection, but their eligibility for the RSV vaccine depends on their age.

Early fertility counseling is necessary for young patients before treatment limits options, said Yara Abdou, MD, of the University of North Carolina at Chapel Hill.

Most Medicare beneficiaries perceived low health care burdens, but 1 in 4 Medicare Advantage enrollees with at least 6 chronic conditions experienced high administrative and financial burdens.

Top content from this year's CHEST meeting in Chicago focused on bronchiectasis treatment, particularly the newly FDA-approved brensocatib (Brinspuri; Insmed).

Treatment-induced menopause can occur with severe symptoms, making personalized management and careful therapy selection essential.

Experts at SABCS 2025 said alcohol consumption raises breast cancer risk, emphasizing the need for public education and clinical intervention.

Four years of long-term data confirm the continued safety of the drug tildrakizumab in patients with psoriatic arthritis.

At SABCS 2025, Amrita Basu, PhD, underscores that effective AI use for breast cancer care depends on human oversight.

Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.

FDA approval of Nirogacistat for desmoid tumors highlights improved survival rates, quality of life, and manageable side effects for patients.

Zachary Contreras of Sharp Health Plan discusses how predictive tools, artificial intelligence-driven analytics, and digital monitoring can help identify treatment-resistant depression early, enabling timely intervention with dextromethorphan-bupropion and reducing clinical and economic burden.

Explore the evolving landscape of desmoid tumor treatments, including chemotherapy, tyrosine kinase inhibitors, and emerging clinical trials.

Zachary Contreras of Sharp Health Plan discusses how dextromethorphan-bupropion may improve agitation management in Alzheimer disease while reducing healthcare costs and supporting patient-centered care.

New research highlights INCA033989's potential in treating mutCALR-driven essential thrombocythemia and myelofibrosis, achieving significant molecular responses.

A small expert panel was selected to share professional experiences with risk-sharing agreements and advance the cost-effective utilization of continuous glucose monitoring–centered care in type 2 diabetes (T2D).

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients.

SABCS 2025 will spotlight new advances in breast cancer research while offering networking opportunities to foster connections among attendees.

Panelists discuss how stigma and symptom overlap delay accurate schizophrenia diagnosis and how early intervention can transform outcomes.

Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH patients.

Panelists discuss how genetics, environment, and substance use interplay to shape schizophrenia risk and guide preventive care.

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.